In last trading session, Summit Therapeutics Inc (NASDAQ:SMMT) saw 3.21 million shares changing hands with its beta currently measuring -0.96. Company’s recent per share price level of $21.57 trading at -$1.89 or -8.06% at ring of the bell on the day assigns it a market valuation of $15.62B. That closing price of SMMT’s stock is at a discount of -57.12% from its 52-week high price of $33.89 and is indicating a premium of 92.4% from its 52-week low price of $1.64. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 3.5 million shares which gives us an average trading volume of 4.99 million if we extend that period to 3-months.
For Summit Therapeutics Inc (SMMT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.67. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.07 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Summit Therapeutics Inc (NASDAQ:SMMT) trade information
Upright in the red during last session for losing -8.06%, in the last five days SMMT remained trading in the green while hitting it’s week-highest on Wednesday, 10/16/24 when the stock touched $21.57 price level, adding 12.17% to its value on the day. Summit Therapeutics Inc’s shares saw a change of 726.44% in year-to-date performance and have moved 15.91% in past 5-day. Summit Therapeutics Inc (NASDAQ:SMMT) showed a performance of -12.17% in past 30-days. Number of shares sold short was 16.34 million shares which calculate 1.53 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 40 to the stock, which implies a rise of 46.08% to its current value. Analysts have been projecting 23 as a low price target for the stock while placing it at a high target of 45. It follows that stock’s current price would drop -6.63% in reaching the projected high whereas dropping to the targeted low would mean a loss of -6.63% for stock’s current value.
Summit Therapeutics Inc (SMMT) estimates and forecasts
Statistics highlight that Summit Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 514.53% of value to its shares in past 6 months, showing an annual growth rate of -107.69% while that of industry is 17.50. Apart from that, the company came lowering its revenue forecast for fiscal year 2024.
Summit Therapeutics Inc (NASDAQ:SMMT)’s Major holders
Insiders are in possession of 84.63% of company’s total shares while institution are holding 10.07 percent of that, with stock having share float percentage of 65.49%. Investors also watch the number of corporate investors in a company very closely, which is 10.07% institutions for Summit Therapeutics Inc that are currently holding shares of the company. BAKER BROS. ADVISORS LP is the top institutional holder at SMMT for having 23.22 million shares of worth $181.13 million. And as of 2024-06-30, it was holding 3.309 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 8.82 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.2566 of outstanding shares, having a total worth of $68.78 million.
